Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10Stomach Neoplasms 6Colorectal Neoplasms 6Biliary Tract Neoplasms 4Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Adenocarcinoma Of Esophagus 2Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Metastatic HER2-positive Breast Cancer 1Hemangiosarcoma 1Head and Neck Neoplasms 1HER2-expressing Cancers 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Advanced Malignancies 1

Interventions

zanidatamab 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2-expressing Cancers × zanidatamab × Clear all
NCT05027139 2025-10-16

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Jazz Pharmaceuticals

Phase 1/2 Completed
52 enrolled

HER2-expressing Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡